Diagnostics and therapy of muscle channelopathies - Guidelines of the Ulm Muscle Centre

Acta Myologica

Volumn 27, Issue DEC., 2008, Pages 98-113

  Lehmann Horn, Frank ^a   Jurkat Rott, K ^a   Rudel R ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

Chloride and sodium channel myotonias; Malignant hyperthermia and central core disease; Periodic paralyses

Indexed keywords

ACETAZOLAMIDE; ANTIDRASI; CARBAMAZEPINE; CREATINE; CREATININE; DANTROLENE; DICLOFENAC; DICLOFENAMIDE; EPLERENONE; FLECAINIDE; FUROSEMIDE; GABAPENTIN; GENE PRODUCT; GLUCONATE CALCIUM; GLUCOSE; HEMOGLOBIN A1C; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MEXILETINE; MODAFINIL; MYOTONIC DYSTROPHY PROTEIN KINASE; ORCIPRENALINE; PHENYTOIN; POTASSIUM; PROPAFENONE; PROTEIN CLC1; SALBUTAMOL; SPIRONOLACTONE; TRIAMTERENE; UNCLASSIFIED DRUG;

ANDERSEN SYNDROME; BECKER MUSCULAR DYSTROPHY; CALCIUM CHANNELOPATHY; CATARACT; CATARACT EXTRACTION; CENTRAL CORE DISEASE; CHANNEL GATING; CHLORIDE CHANNELOPATHY; CLINICAL FEATURE; COGNITIVE DEFECT; COLD SENSITIVITY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; ELECTROCARDIOGRAM; ELECTROMYOGRAM; FATIGUE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENE DELETION; GENETIC COUNSELING; HUMAN; HYPERSOMNIA; HYPOKALEMIC PERIODIC PARALYSIS; IMMUNOGLOBULIN BLOOD LEVEL; MALE TYPE ALOPECIA; MALIGNANT HYPERTHERMIA; MISSENSE MUTATION; MUSCLE ATROPHY; MUSCLE BIOPSY; MUSCLE CHANNELOPATHY; MUSCLE STIFFNESS; MUSCLE WEAKNESS; MYOTONIA; MYOTONIA PERMANENS; MYOTONIC DYSTROPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIODIC PARALYSIS; PHYSIOTHERAPY; POINT MUTATION; POTASSIUM AGGRAVATED MYOTONIA; POTASSIUM BLOOD LEVEL; REVIEW; SODIUM CHANNELOPATHY; THOMSEN DISEASE; THYROID FUNCTION; TRINUCLEOTIDE REPEAT;

CHLORIDE CHANNELS; HUMANS; MALIGNANT HYPERTHERMIA; MYOPATHY, CENTRAL CORE; MYOTONIA; MYOTONIC DYSTROPHY; PARALYSIS, HYPERKALEMIC PERIODIC; SODIUM CHANNELS;

EID: 64949184748     PISSN: 11282460     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Rüdel R, Lehmann-Horn F. Membrane changes in cells from myotonia patients. Physiol Rev 1985;65:310-56.
2. Emery AEH. Diagnostic criteria for neuromuscular disorders. London: Royal Society of Medicine Press 1997.
3. Diener HC. Leitlinien für Diagnostik und Therapie in der Neurologie. 3. Auflage. Stuttgart: Thieme 2008.
4. Mankodi A, Takahashi MP, Jiang H, et al. Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy. Mol Cell 2002;10:35-44.
5. Kwieciński H, Ryniewicz B, Ostrzycki A. Treatment of myotonia with antiarrhythmic drugs. Acta Neurol Scand 1992;86:371-5.
6. Harper P, Monckton DG. Myotonic dystrophy. In: Engel AG, Franzini-Armstrong C, editors. Myology. 3rd ed. New York: McGraw-Hill 2004. pp. 1039-76.
7. Walter MC, Reilich P, Lochmüller H, et al. Creatine monohydrate in myotonic dystrophy: a double-blind, placebo-controlled clinical study. J Neurol 2002;249:1717-22.
8. Tarnopolsky M, Mahoney D, Thompson T, et al. Creatine monohydrate supplementation does not increase muscle strength, lean body mass or phosphocreatine in patients with myotonic dystrophy type 1. Muscle Nerve 2004;29:51-8.
9. Lazarus A, Varin J, Babuty D, Anselme F, et al. Long-term follow-up of arrhythmias in patients with myotonic dystrophy treated by pacing. J. Am Coll Cardiol 2002;40:1645-52.
10. Damian MS, Gerlach A, Schmidt F, et al. Modafinil for excessive daytime sleepiness in myotonic dystrophy. Neurology 2001;56:794-6.
11. Wintzen AR, Lammers GJ, van Dijk JG. Does modafinil enhance activity of patients with myotonic dystrophy: a double blind placebo controlled cross-over study. J Neurol 2007;254:26-8.
12. Ricker K, Koch MC, Lehmann-Horn F, et al. Proximal myotonic myopathy: a new dominant disorder with myotonia muscle weakness, and cataracts. Neurology 1994;44:1448-52.
13. Liquori CL, Ricker K, Moseley ML, et al. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science 2001;293:864-7.
14. Schneider-Gold C, Beck M, Wessig C, et al. Creatine monohydrate in DM2/ PROMM. A double blind placebo-controlled clinical study. Neurology 2003;60:500-2.
15. Lehmann-Horn F, Rüdel R, Jurkat-Rott K. Nondystrophic myotonias and periodic paralysis. In: Engel AG, Franzini-Armstrong C, editors. Myology. 3rd ed. New York: McGraw-Hill; 2004. pp. 1257-300.
16. Rüdel R, Ricker K, Lehmann-Horn F. Transient weakness and altered membrane characteristic in recessive generalized myotonia (Becker). Muscle Nerve 1988;11:202-11.
17. Koch MC, Steinmeyer K, Lorenz C, et al. The skeletal muscle chloride channel in dominant and recessive human myotonia. Science 1992;257:797-800.
18. Pusch M, Steinmeyer K, Koch MC, et al. Mutations in dominant human myotonia congenita drastically alter the voltage dependence of the CIC-1 chloride channel. Neuron 1995;15:1455-63.
19. Lehmann-Horn F, Jurkat-Rott K. Voltage-gated ion channels and hereditary disease. Physiological Reviews 1999;79:1317-71.
20. + channelopathies: MRI detects intracellular 23Na accumulation during episodic weakness. Neurology 2006;67:1151-8.
21. Mohammadi B, Jurkat-Rott K, Alekov A, et al. Preferred mexiletine block of human sodium channels with IVS4 mutations and its pH-dependence. Pharmacogenet Genomics 2005;15:235-44.
22. Alfonsi E, Merlo IM, Tonini M, et al. Efficacy of propafenone in paramyotonia congenita. Neurology 2007;68:1080-1.
23. Heatwole CR, Moxley RT 3rd. The nondystrophic myotonias. Neurotherapeutics 2007;4:238-51.
24. Ricker K, Moxley RT 3rd, Heine R, et al. Myotonia fluctuans, a third type of muscle sodium channel disease. Arch Neurol 1994;51:1095-102.
25. Klingler W, Lehmann-Horn F, Jurkat-Rott K. Complications of anesthesia in neuromuscular disorders. Neuromuscular Disord 2005;15:195-206.
26. Jurkat-Rott K, Lehmann-Horn F. Genotype-phenotype correlation and therapeutic rationale in hyperkalemic periodic paralysis. Neurotherapeutics 2007;4:216-24.
27. Jurkat-Rott K, Lehmann-Horn F. Muscle channelopathies and critical points in functional and genetic studies. J Clin Invest 2005;115:2000-9.
28. Ricker K. Muscle ion channel myotonia. In: Brandt L, Caplan R, Dichgans J, Diener HC, Kennard C, editors. Neurological disorders. Course and treatment. 2nd Edition. USA: Elsevier Science 2003.
29. Fontaine B, Vale-Santos J, Jurkat-Rott K, et al. Mapping of the hypokalaemic periodic paralysis (HypoPP) locus to chromosome 1q31-32 in three European families. Nature Genetics 1994;6:267-72.
30. Jurkat-Rott K, Lehmann-Horn F, Elbaz A, et al. A calcium channel mutation causing hypokalemic periodic paralysis. Hum Mol Genet 1994;3:1415-9.
31. Jurkat-Rott K, Mitrovic N, Hang C, et al. Voltage sensor sodium channel mutations cause hypokalemic periodic paralysis type 2 by enhanced inactivation and reduced current. Proc Natl Acad Sci USA 2000;97:9549-54.
32. Sternberg D, Maisonobe T, Jurkat-Rott K, et al. Hypokalemic periodic paralysis type 2 caused by mutations at codon 672 in the muscle sodium channel gene SCN4A. Brain 2001;124:1091-9.
33. + channel mutant causing hypokalemic periodic paralysis. Biochem Biophys Res Commun 2006;348:653-61.
34. Rüdel R, Lehmann-Horn F, Ricker K, et al. Hypokalemic periodic paralysis: In vitro investigation of muscle fibre membrane parameters. Muscle Nerve 1984;7:110-20.
35. + current. Neurology 1999;53:1556-63.
36. Sokolov S, Scheuer T, Catterall WA. Gating pore current in an inherited ion channelopathy. Nature 2007;446:76-8.
37. + channel mutation linked to hypokalemic periodic paralysis exposes a proton-selective gating pore. J Gen Physiol 2007;130:11-20.
38. Jurkat-Rott K, Lehmann-Horn F. Do hyperpolarisation-induced proton currents contribute to the pathogenesis of hypokalemic periodic paralysis, a voltage sensor channelopathy? J Gen Physiol 2007;130:1-5.
39. +-dependent depolarisation indicate a nonselective cation leak. Submitted to Proc Natl Acad Sci USA (Author: accepted? In press?)
40. Jurkat-Rott K, Lehmann-Horn F. Periodic paralysis mutation MiRP2-R83H in controls: interpretations and general recommendation. Neurology 2004; 62:1012-5.
41. Tawil R, McDermott MP, Brown R Jr, et al. Randomized trials of dichlorophenamide in the periodic paralyses. Working Group on Periodic Paralysis. Ann Neurol 2000;47:46-53.
42. Vicart S, Sternberg D, Fournier E, et al. New mutations of SCN4A cause a potassium-sensitive normokalemic periodic paralysis. Neurology 2004;63:2120-7.
43. Plaster NM, Tawil R, Tristani-Firouzi M, et al. Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome. Cell 2001;105:511-9.
44. Tawil R, Ptaček LJ, Pavlakis SG, et al. Andersen's syndrome: potassium-sensitive periodic paralysis, ventricular ectopy, and dysmorphic features. Ann Neurol 1994;35:326-30.
45. Andelfinger G, Tapper AR, Welch RC, et al. KCNJ2 mutation results in Andersen's syndrome with sex-specific cardiac and skeletal muscle phenotypes. Am J Hum Genet 2002;71:663-8.
46. Venance SL, Cannon SC, Fialho D, et al. The primary periodic paralyses: diagnosis, pathogenesis and treatment. Brain 2006;129:8-17.
47. Junker J, Haverkamp W, Schulze-Bahr E, et al. Amiodarone and acetazolamide for the treatment of genetically confirmed severe Andersen syndrome. Neurology 2002;59:466.
48. Jurkat-Rott K, McCarthy T, Lehmann-Horn F. Genetics and pathogenesis of malignant hyperthermia. Muscle Nerve 2000;23:4-17.
49. Censier K, Urwyler A, Zorzato F, et al. Intracellular calcium homeostasis in human primary muscle cells from malignant hyperthermia-susceptible and normal individuals. Effect of overexpression of recombinant wild-type and Arg163Cys mutated ryanodine receptors. J Clin Invest 1998;101:1233-42.
50. Dietze B, Henke J, Eichinger HM, et al. Malignant hyperthermia mutation Arg615Cys in the porcine ryanodine receptor alters voltage dependence of Ca2+ release. J Physiol 2000;526:507-14.
51. Iaizzo PA, Klein W, Lehmann-Horn F. Fura-2 detected myoplasmic calcium and its correlation with contracture force in skeletal muscle from normal and malignant hyperthermia susceptible pigs. Pflügers Archiv - European J Physiol 1988;411:648-53.
52. Brandt A, Schleithoff L, Jurkat-Rott K, et al. Screening of the ryanodine receptor gene in 105 malignant hyperthermia families: novel mutations and concordance with the in-vitro contracture test. Hum Mol Gen 1999;8:2055-62.
53. 2+ release channel function and severe central core disease. Proc Natl Acad Sci USA 1999;96:4164-9.
54. Avila G, O'Brien JJ, Dirksen RT. Excitation-contraction uncoupling by a human central core disease mutation in the ryanodine receptor. Proc Natl Acad Sci USA 2001;98:4215-20.
55. Avila G, Dirksen RT. Functional effects of central core disease mutations in the cytoplasmic region of the skeletal muscle ryanodine receptor. J Gen Physiol 2001; 118:277-90.
56. Robinson R, Carpenter D, Shaw MA, et al. Mutations in RYR1 in malignant hyperthermia and central core disease. Hum Mutat 2006;27:977-89.
57. Halsall PJ, Bridges LR, Ellis FR, et al. Should patients with central core disease be screened for malignant hyperthermia? J Neurol Neurosurg Psychiatry 1996;61:119-21.
58. 2+ handling caused by malignant hyperthermia and central core disease mutations in RyR1. Biophys J 2004;87:3193-204.
59. 2+ release. Biochem J 2004;382:557-64.
60. De Cauwer H, Heytens L, Martin JJ. Workshop report of the 89th ENMC International Workshop: Central Core Disease, 19th-20th January 2001, Hilversum, The Netherlands. Neuromuscul Disord 2002;12:588-95.
61. North K. Congenital myopathies. In: Engel AG, Franzini-Armstrong C, editors. Myology. 3rd edition. New York: McGraw-Hill 2004. pp. 1473-533.
62. Hagberg JM, Carroll JE, Brooke MH. Endurance exercise training in a patient with central core disease. Neurology 1980;30:1242-4.
63. Zhou H, Jungbluth H, Sewry CA, et al. Molecular mechanisms and phenotypic variation in RYR1-related congenital myopathies. Brain 2007;130:2024-36.
64. Wu S, Ibarra MC, Malicdan MC, et al. Central core disease is due to RYR1 mutations in more than 90% of patients. Brain 2006;129:1470-80.